PAK1 mediates resistance to PI3K inhibition in lymphomas.

ABSTRACT:

Purpose

The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibition across a range of B-cell lymphomas.

Experimental design

We selected three small molecule inhibitors to test in a panel of 60 cell lines that comprised diverse lymphoma types. We tested the selective PI3K inhibitor BKM120 and the dual PI3K/mTOR inhibitors BEZ235 and BGT226 in these cell lines. We applied gene expression profiling to better understand the molecular mechanisms associated with responsiveness to these drugs.

Results

We found that higher expression of the PAK1 gene was significantly associated with resist

SUBMITTER: Walsh K 

PROVIDER: S-EPMC3594365 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature